We leverage our proprietary technology platform to design and deliver safe and effective therapies for neurological disorders.
According to the World Health Organisation (WHO), neurological disorders are one of the greatest threats to public health globally. Over the last couple of decades several strategies have failed to offer safe and effective therapeutic avenues to patients. At SMDG, we leverage our novel platform technology and library of new class of Peptide Conjugate nanoparticles (nanosystems) combined with the next generation nucleic acid therapies designed within our discovery programmes to deliver life saving therapies.
Our primary focus and an expanding portfolio of R & D programmes
Alzheimer's disease (AD) is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks. In most people with the disease—those with the late-onset type—symptoms first appear in their mid-60s.
Parkinson's disease (PD) is a brain disorder that leads to shaking, stiffness, and difficulty with walking, balance, and coordination. Parkinson's symptoms usually begin gradually and get worse over time. As the disease progresses, people may have difficulty walking and talking.
Huntington's disease (HD) is a condition that stops parts of the brain working properly over time. It's passed on (inherited) from a person's parents. Huntington's disease is caused by a faulty gene that results in parts of the brain becoming gradually damaged over time. The patient gets gradually worse over time and is usually fatal after a period of up to 20 years. The symptoms usually start at 30 to 50 years of age, but can begin much earlier or later. Symptoms of Huntington's disease can include: difficulty concentrating and memory lapses, stumbling and clumsiness, involuntary jerking or fidgety, movements of the limbs and body, mood swings and personality changes, problems swallowing, speaking and breathing and difficulty moving.
Rare Neurological Diseases
SMDG is highly committed to leverage its novel new class of nanoparticles and its proprietary platform technology to design and deliver safe and effective therapies for rare neurological disorders.
"A disease is defined as rare if it has a prevalence of less than 5 per 10,000. However, collectively, rare diseases are surprisingly common, creating a huge health-care and economic burden. There are an estimated 5000–8000 rare diseases, and about 5–8% of the European population is thought to be affected by a rare disease, many of which have neurological manifestations. In the U.S.A, it's estimated that over 25-30 million people live with rare diseases. About 80% of rare diseases have a genetic basis, and onset is often in childhood." The Lancet Neurology
Pediatric Rare Diseases
SMDG is focused on designing safe and efficacious therapies for rare pediatric diseases. Neurometabolic disorders are a group of conditions/disorders causing health problems with both metabolism (that disrupt how the body uses or produces energy from food) and brain function. Children with metabolic disorders may manifest neurological signs and symptoms, as well as developmental delays or known neurological problems that turn out to stem from metabolic disorders. Neurometabolic disorders are complex and may result in uncontrollable epilepsy, abnormal movements or loss of developmental milestones starting at a very early age. These defects may be inherited from unaffected parents (healthy carriers) or may be the result of a new change in a child's genes. Pediatric Neuromuscular disorders affect the nerves, especially those outside the brain and spinal cord (peripheral nerves). They also affect skeletal muscles, such as those in the trunk, arms and legs. These disorders can be stable and unchanging or can worsen over time.